Image Ben Hargreaves R&D R&D in 2023 sees focus return to oncology After the rush of research to find solutions to the pandemic, a recent report has found that pharma R&D has returned to its usual rhythms. Market Access Aduhelm and an expensive failure to launch Biogen’s treatment for Alzheimer’s was initially regarded as a major treatment breakthrough. R&D AI and the battle against AMR One of the largest threats facing public health is growing resistance to the world’s existing antibiotics. Oncology Warning signs for CAR-T after secondary cancer cases CAR-T treatments emerged as a major success for the pharma industry when first approved in 2017, but this has been muddied by concerns over secondary malignancies. Load more results
R&D R&D in 2023 sees focus return to oncology After the rush of research to find solutions to the pandemic, a recent report has found that pharma R&D has returned to its usual rhythms.
Market Access Aduhelm and an expensive failure to launch Biogen’s treatment for Alzheimer’s was initially regarded as a major treatment breakthrough.
R&D AI and the battle against AMR One of the largest threats facing public health is growing resistance to the world’s existing antibiotics.
Oncology Warning signs for CAR-T after secondary cancer cases CAR-T treatments emerged as a major success for the pharma industry when first approved in 2017, but this has been muddied by concerns over secondary malignancies.
News DNA testing can help right racial imbalance in breast cancer Study suggests routine genomic testing could correct well-established disparities in breast cancer survival rates between white and black women.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
